Literature DB >> 28846898

Pathogenicity testing of influenza candidate vaccine viruses in the ferret model.

Jessica A Belser1, Adam Johnson1, Joanna A Pulit-Penaloza1, Claudia Pappas1, Melissa B Pearce1, Wen-Pin Tzeng1, M Jaber Hossain1, Callie Ridenour1, Li Wang1, Li-Mei Chen1, David E Wentworth1, Jacqueline M Katz1, Taronna R Maines1, Terrence M Tumpey2.   

Abstract

The development of influenza candidate vaccine viruses (CVVs) for pre-pandemic vaccine production represents a critical step in pandemic preparedness. The multiple subtypes and clades of avian or swine origin influenza viruses circulating world-wide at any one time necessitates the continuous generation of CVVs to provide an advanced starting point should a novel zoonotic virus cross the species barrier and cause a pandemic. Furthermore, the evolution and diversity of novel influenza viruses that cause zoonotic infections requires ongoing monitoring and surveillance, and, when a lack of antigenic match between circulating viruses and available CVVs is identified, the production of new CVVs. Pandemic guidelines developed by the WHO Global Influenza Program govern the design and preparation of reverse genetics-derived CVVs, which must undergo numerous safety and quality tests prior to human use. Confirmation of reassortant CVV attenuation of virulence in ferrets relative to wild-type virus represents one of these critical steps, yet there is a paucity of information available regarding the relative degree of attenuation achieved by WHO-recommended CVVs developed against novel viruses with pandemic potential. To better understand the degree of CVV attenuation in the ferret model, we examined the relative virulence of six A/Puerto Rico/8/1934-based CVVs encompassing five different influenza A subtypes (H2N3, H5N1, H5N2, H5N8, and H7N9) compared with the respective wild-type virus in ferrets. Despite varied virulence of wild-type viruses in the ferret, all CVVs examined showed reductions in morbidity and viral shedding in upper respiratory tract tissues. Furthermore, unlike the wild-type counterparts, none of the CVVs spread to extrapulmonary tissues during the acute phase of infection. While the magnitude of virus attenuation varied between virus subtypes, collectively we show the reliable and reproducible attenuation of CVVs that have the A/Puerto Rico/9/1934 backbone in a mammalian model. Published by Elsevier Inc.

Entities:  

Keywords:  Ferret; Influenza; Pathogenicity; Vaccine viruses

Mesh:

Substances:

Year:  2017        PMID: 28846898      PMCID: PMC5791157          DOI: 10.1016/j.virol.2017.08.024

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  31 in total

1.  The development of vaccine viruses against pandemic A(H1N1) influenza.

Authors:  James S Robertson; Carolyn Nicolson; Ruth Harvey; Rachel Johnson; Diane Major; Kate Guilfoyle; Sarah Roseby; Robert Newman; Rebecca Collin; Chantal Wallis; Othmar G Engelhardt; John M Wood; Jianhua Le; Ramanunninair Manojkumar; Barbara A Pokorny; Jeanmarie Silverman; Rene Devis; Doris Bucher; Erin Verity; Catherine Agius; Sarina Camuglia; Chi Ong; Steven Rockman; Anne Curtis; Peter Schoofs; Olga Zoueva; Hang Xie; Xing Li; Zhengshi Lin; Zhiping Ye; Li-Mei Chen; Eduardo O'Neill; Amanda Balish; Aleksandr S Lipatov; Zhu Guo; Irina Isakova; Charles T Davis; Pierre Rivailler; Kortney M Gustin; Jessica A Belser; Taronna R Maines; Terrence M Tumpey; Xiyan Xu; Jacqueline M Katz; Alexander Klimov; Nancy J Cox; Ruben O Donis
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

2.  Serial passage in ducks of a low-pathogenic avian influenza virus isolated from a chicken reveals a high mutation rate in the hemagglutinin that is likely due to selection in the host.

Authors:  Callie Ridenour; Susan M Williams; Les Jones; S Mark Tompkins; Ralph A Tripp; Egbert Mundt
Journal:  Arch Virol       Date:  2015-07-16       Impact factor: 2.574

3.  Evaluation of a candidate live attenuated influenza vaccine prepared in Changchun BCHT (China) for safety and efficacy in ferrets.

Authors:  Zhenwei Shen; Richard A Bowen; Peng Ge; Jinfei Yu; Yanjie Shen; Wei Kong; Chunlai Jiang; Jinchang Wu; Changlin Zhu; Yanjun Xu; Wei Wei; Larisa Rudenko; Irina Kiseleva; Fei Xu
Journal:  Vaccine       Date:  2016-10-26       Impact factor: 3.641

Review 4.  Rapid production of synthetic influenza vaccines.

Authors:  Philip R Dormitzer
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

5.  Highly pathogenic avian influenza H5N1 viruses elicit an attenuated type i interferon response in polarized human bronchial epithelial cells.

Authors:  Hui Zeng; Cynthia Goldsmith; Pranee Thawatsupha; Malinee Chittaganpitch; Sunthareeya Waicharoen; Sherif Zaki; Terrence M Tumpey; Jacqueline M Katz
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

Review 6.  The ferret as a model organism to study influenza A virus infection.

Authors:  Jessica A Belser; Jacqueline M Katz; Terrence M Tumpey
Journal:  Dis Model Mech       Date:  2011-08-02       Impact factor: 5.758

7.  Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.

Authors:  Callie Ridenour; Adam Johnson; Emily Winne; Jaber Hossain; Guaniri Mateu-Petit; Amanda Balish; Wanda Santana; Taejoong Kim; Charles Davis; Nancy J Cox; John R Barr; Ruben O Donis; Julie Villanueva; Tracie L Williams; Li-Mei Chen
Journal:  Influenza Other Respir Viruses       Date:  2015-09       Impact factor: 4.380

Review 8.  Animal models for influenza viruses: implications for universal vaccine development.

Authors:  Irina Margine; Florian Krammer
Journal:  Pathogens       Date:  2014-10-21

Review 9.  Ferret models of viral pathogenesis.

Authors:  T Enkirch; V von Messling
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

10.  Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.

Authors:  R J Webby; D R Perez; J S Coleman; Y Guan; J H Knight; E A Govorkova; L R McClain-Moss; J S Peiris; J E Rehg; E I Tuomanen; R G Webster
Journal:  Lancet       Date:  2004-04-03       Impact factor: 79.321

View more
  9 in total

1.  Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.

Authors:  Peter Pushko; Irina Tretyakova; Rachmat Hidajat; Xiangjie Sun; Jessica A Belser; Terrence M Tumpey
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

Review 2.  A Guide for the Use of the Ferret Model for Influenza Virus Infection.

Authors:  Jessica A Belser; Alissa M Eckert; Thanhthao Huynh; Joy M Gary; Jana M Ritter; Terrence M Tumpey; Taronna R Maines
Journal:  Am J Pathol       Date:  2019-10-23       Impact factor: 4.307

3.  Extensive T cell cross-reactivity between diverse seasonal influenza strains in the ferret model.

Authors:  Adrian J Reber; Nedzad Music; Jin Hyang Kim; Shane Gansebom; Jufu Chen; Ian York
Journal:  Sci Rep       Date:  2018-04-17       Impact factor: 4.379

4.  Cross-reactive mouse monoclonal antibodies raised against the hemagglutinin of A/Shanghai/1/2013 (H7N9) protect against novel H7 virus isolates in the mouse model.

Authors:  Daniel Stadlbauer; Fatima Amanat; Shirin Strohmeier; Raffael Nachbagauer; Florian Krammer
Journal:  Emerg Microbes Infect       Date:  2018-06-20       Impact factor: 7.163

5.  Genetic Characterization and Zoonotic Potential of Highly Pathogenic Avian Influenza Virus A(H5N6/H5N5), Germany, 2017-2018.

Authors:  Anne Pohlmann; Donata Hoffmann; Christian Grund; Susanne Koethe; Daniela Hüssy; Simone M Meier; Jacqueline King; Jan Schinköthe; Reiner Ulrich; Timm Harder; Martin Beer
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

6.  An In Vitro Microneutralization Assay for Influenza Virus Serology.

Authors:  Frans Cuevas; Hisaaki Kawabata; Florian Krammer; Juan Manuel Carreño
Journal:  Curr Protoc       Date:  2022-07

7.  Avian influenza overview September - November 2017.

Authors:  Ian Brown; Thijs Kuiken; Paolo Mulatti; Krzysztof Smietanka; Christoph Staubach; David Stroud; Ole Roland Therkildsen; Preben Willeberg; Francesca Baldinelli; Frank Verdonck; Cornelia Adlhoch
Journal:  EFSA J       Date:  2017-12-22

8.  Avian influenza overview November 2017 - February 2018.

Authors:  Cornelia Adlhoch; Adam Brouwer; Thijs Kuiken; Paolo Mulatti; Krzysztof Smietanka; Christoph Staubach; Preben Willeberg; Federica Barrucci; Frank Verdonck; Laura Amato; Francesca Baldinelli
Journal:  EFSA J       Date:  2018-03-28

9.  The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets.

Authors:  Mitsutaka Kitano; Takanobu Matsuzaki; Ryoko Oka; Kaoru Baba; Takahiro Noda; Yuki Yoshida; Kenji Sato; Kohei Kiyota; Tohru Mizutare; Ryu Yoshida; Akihiko Sato; Hiroshi Kamimori; Takao Shishido; Akira Naito
Journal:  Influenza Other Respir Viruses       Date:  2020-06-13       Impact factor: 4.380

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.